Established in 2014, Xantho Biotechnology Co., LTD is a research-oriented company specialized in developing new drugs in dermatology.
The new drug GM-XANTHO, developed by Xantho Biotech, is a steroid-free topical ointment for the treatment of atopic dermatitis (AD). The efficacy and safety of GM-XANTHO in patients with atopic dermatitis are currently being studied in a double-blinded, placebo-controlled phase 2a clinical trial, and the interim analysis result will be available in 2023 Q2.
We are looking to collaborate with pharmaceutical companies and investors to offer a better drug for AD patients. GM-XANTHO is available for out-licensing and we are seeking partners for drug development and commercialization.
For more information please visit https://xanthobio.com/en/
The new drug GM-XANTHO, developed by Xantho Biotech, is a steroid-free topical ointment for the treatment of atopic dermatitis (AD). The efficacy and safety of GM-XANTHO in patients with atopic dermatitis are currently being studied in a double-blinded, placebo-controlled phase 2a clinical trial, and the interim analysis result will be available in 2023 Q2.
We are looking to collaborate with pharmaceutical companies and investors to offer a better drug for AD patients. GM-XANTHO is available for out-licensing and we are seeking partners for drug development and commercialization.
For more information please visit https://xanthobio.com/en/
Focus Areas